Anuh Pharma Ltd. (BSE: 506260) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹829 Cr, it ranks #1,686 by market cap among the 6,197 Indian listed companies on FinBizNet, and #49 of 86 in Medicinal Chemicals and Botanical Products. At ₹82.50 (as of 16 Nov 2026), the share price is 17.1% below its 52-week high of ₹99.50 and 23.1% above its 52-week low of ₹67.00. The share price is down 4.0% over one year and up 7.1% over three months.
| Current Price | ₹82.50 |
|---|---|
| Market Cap | ₹829 Cr |
| BSE Code | 506260 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 20.2 |
| Return on Equity | 12.10% |
| Return on Assets | 6.63% |
| 52-Week Range | ₹67.00 – ₹99.50 |
| 1-Year Price Change | -4.0% |
| 3-Month Price Change | +7.1% |
| Beta (1Y) | 0.3 |
| Dividend Yield | 1.81% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.anuhpharma.com |
| Revenue | ₹185 Cr |
|---|---|
| Net Profit | ₹11 Cr |
| Net Margin | 6.1% |
| EPS (Basic) | ₹1.12 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Anuh Pharma Ltd. reported revenue of ₹185 Cr in Q2 FY27, down 0.3% from ₹186 Cr in Q2 FY26 and down 4.4% from ₹194 Cr in Q1 FY27. It posted a net profit of ₹11 Cr for the quarter, against a net profit of ₹8 Cr in Q2 FY26 (up 47.3%). Across the 8 quarters from Q3 FY25 to Q2 FY27, quarterly revenue ranged from ₹160 Cr (Q3 FY25) to ₹202 Cr (Q4 FY26). The company was profitable in each of these 8 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹185 Cr | ₹11 Cr | 6.1% |
| Q1 FY27 | ₹194 Cr | ₹11 Cr | 5.9% |
| Q4 FY26 | ₹202 Cr | ₹12 Cr | 5.8% |
| Q3 FY26 | ₹197 Cr | ₹13 Cr | 6.8% |
| Q2 FY26 | ₹186 Cr | ₹8 Cr | 4.1% |
| Q1 FY26 | ₹186 Cr | ₹8 Cr | 4.5% |
| Q4 FY25 | ₹198 Cr | ₹12 Cr | 6.3% |
| Q3 FY25 | ₹160 Cr | ₹10 Cr | 6.5% |
Standalone figures (₹ crore, XBRL filings).
Promoters held 71.80% of Anuh Pharma Ltd.'s shares as of Sept 2026, against 71.82% in Sept 2025 (−0.02 percentage points). Delivery averaged 54.0% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Anuh Pharma Limited engages in the manufacture and sale of bulk drugs and chemicals in India. It offers active pharmaceutical ingredients, including macrolides, anti-TB, anti-bacterial, anti-asthmatics, anti-diabetics, intermediates, expectorant, quinolones, anti-malarial, anti-gout, anti-biotic, anti-platelet, and antihistamines; and corticosteroids, including anti-inflammatory, immunosuppressant, anti-pruritic, anti-mitotic. The company also develops products, such as coagulants, gastrointestinal, anti convulsants, and cholesterol drugs. It also exports its products. The company was incorporated in 1960 and is headquartered in Mumbai, India.
1. Bulk Drug and Chemicals-This segment manufactures and sells bulk drugs and chemicals.
1. Bulk Drug and Chemicals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Anuh Pharma Ltd. | ₹829 Cr | 20.2 | 12.10% | ₹185 Cr | -4.0% |
Listed by market capitalisation. Ratios are shown for context only.
Anuh Pharma Ltd. is trading at ₹82.50, with a market capitalisation of ₹829 Cr.
Anuh Pharma Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Anuh Pharma Ltd. has a P/E of 20.2 and a return on equity of 12.10%.
Anuh Pharma Ltd. is listed on the BSE under the scrip code 506260.
Anuh Pharma Ltd.'s share price is down 4.0% over one year and up 7.1% over three months. Its 52-week range is ₹67.00 to ₹99.50.
In Q2 FY27, Anuh Pharma Ltd. reported revenue of ₹185 Cr and net profit of ₹11 Cr, with basic EPS of ₹1.12 (standalone, parsed from the company's exchange filing).
Anuh Pharma Ltd. reported revenue of ₹185 Cr in Q2 FY27, down 0.3% from ₹186 Cr in Q2 FY26 and down 4.4% from ₹194 Cr in Q1 FY27.
Promoters held 71.80% of Anuh Pharma Ltd.'s shares as of Sept 2026, against 71.82% in Sept 2025 (−0.02 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.